+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Bavarian Nordic AS (BAVA) - Financial and Strategic SWOT Analysis Review

  • PDF Icon

    SWOT Analysis

  • 59 Pages
  • May 2023
  • Region: Denmark, Finland, Iceland, Norway, Sweden
  • GlobalData
  • ID: 4284899
Bavarian Nordic AS (BAVA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the publisher to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Bavarian Nordic AS (Bavarian Nordic) is a vaccine company that develops, manufactures and commercializes vaccines for the prevention of life-threating diseases. The company develops its products using poxvirus-based technology platforms including modified vaccinia Ankara -Bavarian Nordic (MVA-BN). The company’s marketed products include JYNNEOS for smallpox and monkeypox; Encepur for tick-borne encephalitis; MVABEA for ebola; and Rabipur/RabAvert for rabbies. Its pipeline products are intended for the treatment of smallpox, COVID-19, respiratory syncytial virus, HER2- and brachyury-expressing cancers and Ebola infections. Bavarian Nordic has collaboration with the US government and various institutes, to develop its product candidates for the treatment of cancer and infectious diseases. It has a presence in the US, Denmark, Switzerland and Germany. Bavarian Nordic is headquartered in Hellerup, Denmark.

Bavarian Nordic AS Key Recent Developments

  • Apr 18, 2023: Developers of mpox diagnostic kits, vaccines receive attention as mpox spreads in Korea
  • Mar 07, 2023: Bavarian Nordic Notice Convening Annual General Meeting
  • Mar 02, 2023: Bavarian Nordic Publishes Annual Report 2022
  • Feb 24, 2023: Bavarian Nordic to Host Full Year 2022 Results Conference Call

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • Bavarian Nordic AS - Key Facts
  • Bavarian Nordic AS - Key Employees
  • Bavarian Nordic AS - Key Employee Biographies
  • Bavarian Nordic AS - Major Products and Services
  • Bavarian Nordic AS - History
  • Bavarian Nordic AS - Company Statement
  • Bavarian Nordic AS - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Company Overview
  • Bavarian Nordic AS - Business Description
  • Product Category: Contract Work
  • Overview
  • Performance
  • Product Category: Encepur
  • Overview
  • Performance
  • Product Category: Milestone Payments
  • Performance
  • Product Category: MVA-BN Smallpox Vaccine Sale
  • Overview
  • Performance
  • Product Category: Other Product Sale
  • Overview
  • Performance
  • Product Category: Rabipur/RabAvert
  • Overview
  • Performance
  • Geographical Segment: Australia
  • Performance
  • Geographical Segment: Belgium
  • Performance
  • Geographical Segment: Canada
  • Performance
  • Geographical Segment: France
  • Performance
  • Geographical Segment: Germany
  • Performance
  • Geographical Segment: Hong Kong
  • Performance
  • Geographical Segment: Other geographic markets
  • Performance
  • Geographical Segment: Saudi Arabia
  • Performance
  • Geographical Segment: Switzerland
  • Performance
  • Geographical Segment: United Kingdom
  • Performance
  • Geographical Segment: USA
  • Performance
  • R&D Overview
  • Bavarian Nordic AS - Corporate Strategy
  • Bavarian Nordic AS - SWOT Analysis
  • SWOT Analysis - Overview
  • Bavarian Nordic AS - Strengths
  • Bavarian Nordic AS - Weaknesses
  • Bavarian Nordic AS - Opportunities
  • Bavarian Nordic AS - Threats
  • Bavarian Nordic AS - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences, Power Financial Deals and Alliances
  • Bavarian Nordic AS, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Bavarian Nordic AS, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
  • Bavarian Nordic AS, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • Apr 18, 2023: Developers of mpox diagnostic kits, vaccines receive attention as mpox spreads in Korea
  • Mar 07, 2023: Bavarian Nordic Notice Convening Annual General Meeting
  • Mar 02, 2023: Bavarian Nordic Publishes Annual Report 2022
  • Feb 24, 2023: Bavarian Nordic to Host Full Year 2022 Results Conference Call
  • Feb 20, 2023: Bavarian Nordic Launches Offering of up to 7,046,839 New Shares in a Directed Issue
  • Feb 15, 2023: Bavarian Nordic Provides Pipeline Update and Financial Guidance for 2023
  • Jan 16, 2023: Bavarian Nordic Reports Better Than Expected Preliminary Financial Results for 2022
  • Dec 14, 2022: Ebola Vaccine regimens safe, immunogenic in adults and children
  • Nov 09, 2022: Bavarian Nordic Announces Interim Results for the First Nine Months of 2022
  • Nov 02, 2022: Bavarian Nordic to Host Third Quarter 2022 Results Conference Call
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Publisher
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Bavarian Nordic AS, Key Facts
  • Bavarian Nordic AS, Key Employees
  • Bavarian Nordic AS, Key Employee Biographies
  • Bavarian Nordic AS, Major Products and Services
  • Bavarian Nordic AS, History
  • Bavarian Nordic AS, Other Locations
  • Bavarian Nordic AS, Subsidiaries
  • Bavarian Nordic AS, Key Competitors
  • Bavarian Nordic AS, Ratios based on current share price
  • Bavarian Nordic AS, Annual Ratios
  • Bavarian Nordic AS, Interim Ratios
  • Bavarian Nordic AS, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Bavarian Nordic AS, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
  • Bavarian Nordic AS, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Bavarian Nordic AS, Performance Chart (2018 - 2022)
  • Bavarian Nordic AS, Ratio Charts
  • Bavarian Nordic AS, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Bavarian Nordic AS, Pharmaceuticals & Healthcare, Deals by Type, 2017 to YTD 2023

Samples

Loading
LOADING...

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Moderna Inc
  • Virometix AG
  • BioNTech SE
  • Icosavax Inc
  • Virometix AG
  • Novavax Inc
  • Moderna Inc
  • Icosavax Inc
  • BioNTech SE
  • Novavax Inc